Guy Neff
Gastroenterology · Sarasota, FLNPI 1477510931
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 58.9% of the total. Reporting peaked in 2023 at $26,119 and has fallen 75.0% since, to $6,537 in 2024. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $1275.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$31K
- Intercept Pharmaceuticals, Inc.$18K
- Novo Nordisk$2K
- Gilead$1K
- Boehringer Ingelheim$48
- E.r. Squibb & Sons, L.L.C.$16
Across 3,878 payments — averaging $4537.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$7.5M
- Boehringer Ingelheim International GmbH$6.5M
- Madrigal Pharmaceuticals$1.4M
- Gilead$1.2M
- E.r. Squibb & Sons, L.L.C.$370K
- Novartis$180K
- plus $395K from 11 others
What the payments were for
- Consulting fees$15,86030%
- Speaking & faculty fees$20,23839%
- Travel & lodging$15,49330%
- Food & beverage$6751%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 19 | $30,807 |
| Intercept Pharmaceuticals, Inc. | 17 | $18,400 |
| Novo Nordisk | 2 | $1,800 |
| Gilead | 1 | $1,210 |
| Boehringer Ingelheim | 1 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$18,285
How this compares
$52,282 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 54 | $582 |
| Tramadol Hcl | 36 | $60 |
| Alprazolam | 49 | $49 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Sarasota
- Marc BernsteinSarasota$199K
- Charles LoeweSarasota$98K
- Benjamin RodriguezSarasota$69K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.